Sun Pharma's guidance for FY26 suggests that overhead spends shall rise ahead of revenue growth, adversely impacting earnings ...

Welcome to the Sun Pharma Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most ...

Sun Pharma’s Q4 consolidated net profit fell 19% YoY to ₹2,154 crore, despite an 8% rise in revenue to ₹12,959 crore.